---
title: "KOD.US (KOD.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KOD.US/news.md"
symbol: "KOD.US"
name: "KOD.US"
parent: "https://longbridge.com/en/quote/KOD.US.md"
datetime: "2026-05-21T12:07:36.504Z"
locales:
  - [en](https://longbridge.com/en/quote/KOD.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KOD.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KOD.US/news.md)
---

# KOD.US (KOD.US) — Related News

### [Kodiak Sciences Zenkuda Data Shifts Focus To Retinal Pipeline Value](https://longbridge.com/en/news/285822282.md)
*2026-05-09T22:04:09.000Z*
> Kodiak Sciences (NasdaqGM:KOD) announced positive Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy, supporting 

### [LifeSci Capital Remains a Buy on Kodiak Sciences (KOD)](https://longbridge.com/en/news/285747453.md)
*2026-05-08T14:56:13.000Z*
> LifeSci Capital analyst Patrick Dolezal has maintained a Buy rating on Kodiak Sciences (KOD) with a price target of $65.

### [Kodiak Sciences | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/285606535.md)
*2026-05-07T20:02:17.000Z*
### [Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results | KOD Stock News](https://longbridge.com/en/news/285606116.md)
*2026-05-07T12:01:15.000Z*
> Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results | KOD Stock News

### [Will Positive Asian MESI Data and Phase 3 Expansion Reshape Kodiak Sciences' (KOD) Eye-Drug Narrative?](https://longbridge.com/en/news/285105403.md)
*2026-05-04T18:05:42.000Z*
> Kodiak Sciences is presenting new clinical data for its bispecific eye therapy KSI-101, showing positive results from Ph

### [Kodiak Sciences Inc. $KOD Stock Holdings Decreased by RIA Advisory Group LLC](https://longbridge.com/en/news/284994537.md)
*2026-05-03T12:17:27.000Z*
> RIA Advisory Group LLC has reduced its stake in Kodiak Sciences Inc. (NASDAQ:KOD) by 31.9% in Q4, now holding 113,473 sh

### [Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences | KOD Stock News](https://longbridge.com/en/news/284865243.md)
*2026-04-30T20:25:33.000Z*
> Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertia